Curtis Lachowiez

22PUBLICATIONS
160CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markersHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Mar 31, 2026
Models, Models, Everywhere: But Which One Should Guide Care?

Curtis A Lachowiez, Sanam Loghavi

|Nov 05, 2025
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Sven Turkalj, Felix A Radtke, Bilyana Stoilova

|Jul 03, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard

|Jun 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Joshua F Zeidner, Tara L Lin, Rina Li Welkie

Pageof 4

Frequent Collaborators

10 joint publications

Courtney D DiNardo

10 joint publications

Sanam Loghavi

8 joint publications

Naval G Daver

6 joint publications

Tapan M Kadia